Tianjin Pharma Completes Biannual Risk Assessment

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has conducted a rigorous biannual risk assessment of its subsidiary, Tianjin Pharmaceutical Group Finance Co., Ltd. (TPGF), as mandated by the Shanghai Stock Exchange. The assessment, which includes an analysis of TPGF’s financial statements and business licenses, is part of a compliance process following the company’s financial service agreement with TPGF that spans from July 2023 to June 2026. The board has confirmed the accuracy and fairness of the disclosed information in this update.

For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.